http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2014200085-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1dfd845abd1b15aeeb9bdf1f1eabc338 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-42 |
filingDate | 2014-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_43b95554ab00bb0d7dd20076d6d9c9ef http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f553f8a8ec91630340688d530bfb5bd5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6e9d79151a63704a431667ee9fa61d1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd12ce3c707c6fbc6d5b5b4b61717055 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bacdd516ba8fdc51db5f56bfa4330f87 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a66a49a7c9c9b813821cda8a2f63658f |
publicationDate | 2014-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | AU-2014200085-A1 |
titleOfInvention | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use |
abstract | H:\amft\Inten voyen\NRPortbl\DCC\AM\5928962_.DOC.7/01/2014 The present invention provides compositions containing clopidogrel, present as a free base or a pharmaceutically acceptable salt thereof, and sulfoalkyl ether cyclodextrin (SAE-CD). The compositions can be liquid, suspension or solid compositions. They can be adapted for oral, peroral or parenteral administration. The SAE-CD serves to aid in dissolution and stabilization of the clopidogrel in aqueous media. The stability of clopidogrel against hydrolytic de gradation, thermal deg radation, an d photol ytic de gradation are improved. SAE-CD provides improved results over other cyclodextrin derivatives. The SAE-CD containing composition of clopidogrel can be provided in liquid form, solid form or as a reconstitutable powder. Both ready-to-use and concentrated liquid compositions can be prepared. The liquid composition is optionally available as a clear solution. The compositions herein can be administered perorally or parenterally and provide substantial pharmacokinetic, pharmacodynamic and/or therapeutic advantages over a tablet composition administered perorally and excluding SAE-CD. |
priorityDate | 2007-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 296.